tiprankstipranks
Oncology Institute, Inc. (TOI)
:TOI
US Market
Holding TOI?
Track your performance easily

Oncology Institute, Inc. (TOI) Earnings Dates, Call Summary & Reports

59 Followers

Earnings Data

Report Date
Mar 06, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
Last Year’s EPS
Same Quarter Last Year
Based on 0 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:May 11, 2022
|
% Change Since: 111.54%
|
Next Earnings Date:Mar 10, 2022
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth, strategic expansions, and operational improvements, such as cost reductions and cash surplus. However, challenges remain with net losses, negative adjusted EBITDA, and compliance issues with NASDAQ. Despite these challenges, the positive aspects, especially in revenue and operational efficiencies, suggest a cautiously optimistic outlook.
Company Guidance
During The Oncology Institute's third-quarter 2024 earnings call, several metrics highlighted the company's financial performance and strategic initiatives. Revenue grew by 21.8% compared to the previous year, reaching $99.9 million, largely driven by an 80% increase in oral drug revenue. The company achieved a gross profit of $14.4 million, marking a 10.3% improvement from the previous quarter. SG&A expenses were reduced by 6% year-over-year, maintaining flat at $28.2 million, showcasing efficiency improvements. Despite a net loss of $16.1 million, this represented an improvement of $1.3 million from Q3 2023. Additionally, cash and cash equivalents increased by $1 million from the previous quarter, and a favorable legal settlement is expected to bring in an additional $4.1 million in Q4. The company also signed 13 new capitation contracts year-to-date and achieved certification for Radiopharmaceutical Therapy, positioning it for continued growth and improved margins.
Revenue Growth
Overall revenue grew 21.8% in the third quarter compared to the prior year period, driven by an exceptional oral drug revenue growth of approximately 80%.
Capitation Contracts
Signed an additional 3 capitation contracts across 2 states, including the first capitation contract in Oregon.
Radiopharmaceutical Therapy Certification
Achieved certification to begin Radiopharmaceutical Therapy in California, expected to be a significant growth driver.
Cash Surplus
Cash and cash equivalents increased by $1 million compared to Q2 2024, marking the first quarterly cash surplus this year.
SG&A Expense Reduction
Generated a 6% reduction in SG&A expenses compared to the prior year, showcasing efforts to streamline operations.
Improved Gross Margin
Gross profit for Q3 2024 was $14.4 million, an increase of 10.3% compared to Q2 2024, attributed to improved IV margins.
Legal Settlement Cash Inflow
A favorable legal settlement in Q4 is expected to generate a cash inflow of $4.1 million.
---

Oncology Institute, Inc. (TOI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TOI Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 10, 20222021 (Q4)
- / -0.15
-0.2846.43% (+0.13)
May 11, 20222022 (Q1)
- / 0.25
0.19827.78% (+0.05)
Aug 09, 20222022 (Q2)
- / -0.09
-0.21357.75% (+0.12)
Nov 09, 20222022 (Q3)
-0.18 / -0.17
-0.015-1033.33% (-0.16)
Mar 09, 20232022 (Q4)
-0.20 / -0.16
-0.15-6.67% (-0.01)
May 10, 20232023 (Q1)
- / -0.33
0.253-230.43% (-0.58)
Aug 08, 20232023 (Q2)
-0.17 / -0.19
-0.09-111.11% (-0.10)
Nov 08, 20232023 (Q3)
-0.13 / -0.19
-0.17-11.76% (-0.02)
Mar 27, 20242023 (Q4)
-0.11 / -0.21
-0.16-31.25% (-0.05)
May 14, 20242024 (Q1)
-0.12 / -0.22
-0.3333.33% (+0.11)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

TOI Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2024$0.26$0.24-7.69%
Aug 13, 2024$0.55$0.45-18.18%
May 14, 2024$0.90$0.68-24.44%
Mar 27, 2024$1.84$1.58-14.13%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Oncology Institute, Inc. (TOI) report earnings?
Oncology Institute, Inc. (TOI) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
    What is Oncology Institute, Inc. (TOI) earnings time?
    Oncology Institute, Inc. (TOI) earnings time is at Mar 06, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TOI EPS forecast?
          Currently, no data Available
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis